Managers / Q3 2020 · view latest →
Foresite Capital Management IV, LLC
CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management IV, LLC reported $443M in U.S.-listed holdings across 15 positions for Q3 2020.
The portfolio is heavily concentrated: RLAY alone accounts for 20.5% of reported value.
Compared with Q2 2020, the fund opened 7 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 98.5% · $437M
- Other · 1.5% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RLAYRelay Therapeutics, Inc. | NEW | +2.14M | 2.14M | +$91M | $91M |
| NRIXNurix Therapeutics, Inc. | NEW | +2.35M | 2.35M | +$82M | $82M |
| ALXOALX Oncology Holdings Inc. | NEW | +973.5K | 973.5K | +$37M | $37M |
| ABUSArbutus Biopharma Corp | NEW | +3.33M | 3.33M | +$10M | $10M |
| Therapeutics Acquisition Corp | NEW | +350.0K | 350.0K | +$5M | $5M |
| Panacea Acquisition Corp | NEW | +150.0K | 150.0K | +$2M | $2M |
| ACRSAclaris Therapeutics, Inc. | NEW | +144.9K | 144.9K | +$372,000 | $372,000 |
| FULCFulcrum Therapeutics, Inc. | SOLD OUT | −1.13M | 0 | −$21M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RLAYRelay Therapeutics, Inc.history → | COM | 20.55% | $91M | 2.14M |
| 2 | NRIXNurix Therapeutics, Inc.history → | COM | 18.48% | $82M | 2.35M |
| 3 | KROSKeros Therapeutics, Inc.history → | COM | 12.29% | $54M | 1.41M |
| 4 | KURAKura Oncology, Inc.history → | COM | 9.04% | $40M | 1.31M |
| 5 | ALXOALX Oncology Holdings Inc.history → | COM | 8.29% | $37M | 973.5K |
| 6 | CYTKCytokinetics Incorporatedhistory → | COM | 8.16% | $36M | 1.67M |
| 7 | Generation Bio Co. | COM | 5.98% | $27M | 857.9K |
| 8 | PCVXVaxcyte, Inc.history → | COM | 5.19% | $23M | 465.8K |
| 9 | Myokardia, Inc. | COM | 3.89% | $17M | 126.5K |
| 10 | Cymabay Therapeutics, Inc. | COM | 2.92% | $13M | 1.79M |
| 11 | ABUSArbutus Biopharma Corphistory → | COM | 2.35% | $10M | 3.33M |
| 12 | VYGRVoyager Therapeutics, Inc.history → | COM | 1.24% | $6M | 516.8K |
| 13 | Therapeutics Acquisition Corp | COM CL A | 1.13% | $5M | 350.0K |
| 14 | Panacea Acquisition Corp | UNIT | 0.41% | $2M | 150.0K |
| 15 | ACRSAclaris Therapeutics, Inc. | COM | 0.08% | $372,000 | 144.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $237M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $230M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $183M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $124M | 6 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $111M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $109M | 4 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $153M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $149M | 4 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $198M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $198M | 5 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $180M | 7 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $203M | 7 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $193M | 8 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $234M | 8 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $311M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $371M | 8 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $357M | 9 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $486M | 9 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $679M | 12 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $740M | 13 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $835M | 13 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $921M | 13 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $443M | 15 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $205M | 12 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $81M | 11 | May 28, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2019 | $232M | 14 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $309M | 19 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $354M | 22 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $278M | 16 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.